/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.03%
Natural Gas
-3.02%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.02%
VIX
N/A
Economic Calendar
EUR/USD
-0.03%
Natural Gas
-3.02%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.02%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Bitcoin ETFs: After Record $328M Outflows, What Happens Next?
about 4 hours ago
Vitalik Buterin Backs Ethereum PoS Transition amid Community Debates
about 5 hours ago
Crypto Market Outlook: BTC, SOL, ETH, DOGE Face Downward Pressure
about 6 hours ago
Crypto Market Recap: Ripple (XRP), SHIB and Binance Seize the Limelight
about 14 hours ago
The Week Ahead: US Jobs Report, the Fed, China Stats, and Yen Intervention Chatter
about 19 hours ago
Can Amazon and Apple Uphold the S&P 500’s Lofty Valuations?
1 day ago
PEPE Price Forecast: What Next after 65% Gains in 10-days
about 2 hours ago
Dogecoin (DOGE) Price Forecast: What Next After Holding $0.15 Support?
about 5 hours ago
Optimism (OP) Price Prediction: Bulls Aiming for $4 Retest after 20% Gains
about 4 hours ago
Week Ahead: FOMC and Jobs Data in Sight
about 11 hours ago
USD/JPY Closing in on 1990 Highs
about 11 hours ago
EUR/USD: Bears to Remain in Control from $1.07?
about 11 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
BMRN
profile
Biomarin Pharmaceutical Inc. - Registered Shares
Follow
BMRN
(
Nasdaq - US
)
N/A
80.92
-1.25 (-1.52%)
in
:
usd
•
As of: Apr 26, 2024 15:59
UTC -4
Open
82.00
High
83.10
Low
80.92
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Biomarin Pharmaceutical Inc. - Registered Shares
CEO
Alexander Hardy
Headquarters
770 lindaro street
san rafael, ca 94901, united states
Auditor
KPMG LLP
Employees
3,401
Share Holders
34
Website
www.bmrn.com
Industry
biotechnology
Sector
health technology
Company Overview
BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Biomarin Pharmaceutical Inc. - Registered Shares
Statistics
Valuation Measures
Market Capitalization
2
15.27B
Enterprise Value
15.60B
Enterprise Value/EBITDA
(ttm)
61.61
Price to Earnings Ratio
(ttm)
59.93
Price to Book
(mrq)
3.08
Price to Sales
(ttm)
6.18
Price to Cash
(ytd)
45.23
Profitability
Gross Margin
(ttm)
78.71%
Operating Margin
(ttm)
10.64%
Profit Margin
(ttm)
7.01%
Return on Equity
(ttm)
5.39%
Return on Invested Capital
(ttm)
2.94%
Return on Assets
(ttm)
3.91%
Income Statement
Revenue
(ttm)
2.42B
Revenue Per Share
(ttm)
12.82
Gross Profit
(ttm)
1.90B
EBITDA
(ttm)
3
253.26M
Net Income Avi to Common
(ttm)
167.65M
Diluted EPS
(ttm)
1.07
Share Statistics
Beta (5Y Monthly)
0.31
52-Week Change
-15.74%
S&P500 52-Week Change
25.74%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
188.68M
Dividend Yield
0.00%
Float
4
185.26M
%
Held by Insiders
1.84%
%
Held by Institutions
98.71%
Balance Sheet
Total Cash
(mrq)
1.07B
Total Cash Per Share
(mrq)
5.69
Total Debt
(mrq)
1.09B
Total Debt/Equity
(mrq)
21.95%
Current Ratio
(mrq)
2.51%
Quick Ratio
(mrq)
1.57%
Book Value Per Share
(mrq)
26.25
Cash Flow
Operating Cash Flow Per Share
(ytd)
0.83
Free Cash Flow
(ytd)
62.57M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker